Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663327 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| SCHEMBL1598306 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| SCHEMBL553866 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| SCHEMBL553865 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| SCHEMBL553583 | 0.80 | USP2 (0.47) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| SCHEMBL554651 | 0.80 | USP2 (0.47) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| SCHEMBL553582 | 0.80 | USP2 (0.47) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| Hydrochloric Acid SCHEMBL28718255 | 0.79 | USP2 (0.46) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| SCHEMBL307099 | 0.79 | PDK1 (0.49) | SMN1; SMN2USP2IL1BP2RX7ATM | |
| SCHEMBL20371626 | 0.79 | USP2 (0.49) | SMN1; SMN2USP2IL1BP2RX7ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3484886-B1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3484886-B1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3484886-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | Hoffmann-La Roche AG (CH) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018011163-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011163-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | CYP3A5, RRP15, HAVCR2 | SMN1; SMN2 3207/4885USP2 4173/4885IL1B 829/4885 |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | CYP3A5, RRP15, QDPR | SMN1; SMN2 3115/4885USP2 4466/4885IL1B 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.